Search

Search bills, members, committees and pages...

S. 2620

U.S. SenateIn Senate Committee

Summary

S. 2620, the REMEDY Act, was introduced in the Senate on Jul 31, 2025 by Sen. Richard Durbin (D) with 1 co-sponsor. It was referred to Health, Education, Labor, And Pensions, and last saw action on Jul 31, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000).


Record

Text

S. 2620 has 1 co-sponsor.

sb2620/introduced-in-senate.txt
119 S2620 IS: Reforming Evergreening and Manipulation that Extends Drug Years Act
U.S. Senate
2025-07-31
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
II
119th CONGRESS
1st Session
S. 2620
IN THE SENATE OF THE UNITED STATES
July 31, 2025
Mr. Durbin (for himself and Mr. Cassidy ) introduced the following bill; which was
read twice and referred to the Committee on
Health, Education, Labor, and Pensions
A BILL
To amend the Federal Food, Drug, and Cosmetic Act with respect to approval
of abbreviated new drug applications.
1.
Short title
This Act may be cited as the Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act .
2.
Amendments to ANDA approval provisions
Section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) is amended—
(1)
in subsection (c)(2) by adding at the end the following: With respect to a drug approved on or after the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , when a holder of an approved application first files information under this paragraph with respect to one or more patents described in subsection (b)(1)(A)(viii), the holder shall select one such patent with respect to which the owner or licensee may be eligible for the thirty-month period under paragraph (3)(C) or subsection (j)(5)(B)(iii), as applicable; for purposes of paragraphs (3)(C) and (3)(E)(ii) and subsections (j)(5)(B)(iii) and (j)(5)(F)(ii), such patent shall be referred to as the covered patent . The selection of such covered patent may not be changed or amended. ;
(2)
in subsection (c)(3)(C)—
(A)
in the matter preceding clause (i)—
(i)
by striking an action is brought for infringement and all that follows through the period at the end of the first sentence and inserting with respect to a drug approved under this subsection before the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of any patent that is the subject of the certification and for which information was submitted to the Secretary under paragraph (2) before the date on which the application (excluding an amendment or supplement to the application) was submitted, or, with respect to a drug approved under this subsection on or after the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of the covered patent (as described in paragraph (2)) that is the subject of the certification and for which information was submitted to the Secretary under paragraph (2) before the date on which the application (excluding an amendment or supplement to the application) was submitted. ; and
(ii)
by striking an action is brought before and inserting an action with respect to a patent or a covered patent, as applicable, is brought before ; and
(B)
in clause (i), by striking decides that the patent and inserting decides that the patent or the covered patent, as applicable ;
(3)
in the second sentence of subsection (c)(3)(E)(ii), by inserting with respect to any patent for which the requirements are met for the thirty-month period described in subparagraph (C) after action for patent infringement ;
(4)
in subsection (j)(5)(B)(iii)—
(A)
in the matter preceding subclause (I)—
(i)
by striking an action is brought for infringement and all that follows through the period at the end of the first sentence and inserting with respect to a drug approved under subsection (c) before the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of any patent that is the subject of the certification and for which information was submitted to the Secretary under subsection (c)(2) before the date on which the application (excluding an amendment or supplement to the application), which the Secretary later determines to be substantially complete, was submitted, or, with respect to a drug approved under subsection (c) on or after the date of enactment of the Reforming Evergreening and Manipulation that Extends Drug Years Act , an action is brought for infringement of the covered patent (as described in subsection (c)(2)) that is the subject of the certification and for which information was submitted to the Secretary under subsection (c)(2) before the date on which the application (excluding an amendment or supplement to the application), which the Secretary later determines to be substantially complete, was submitted. ; and
(ii)
by striking an action is brought before and inserting an action with respect to a patent or a covered patent, as applicable, is brought before ; and
(B)
in subclause (I), by striking decides that the patent and inserting decides that the patent or covered patent, as applicable, ; and
(5)
in the second sentence of subsection (j)(5)(F)(ii), by inserting with respect to any patent for which the requirements are met for the thirty-month period described in subparagraph (B)(iii), after action for patent infringement .

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-07-31
  2. Passed Senate
  3. Passed House
  4. Conference
  5. To President
  6. Became Law

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Introduced in Senate Jul 31, 2025

sb2620/introduced-in-senate.md

Shown Here:
Introduced in Senate (07/31/2025)

Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act

This bill limits the scope of a 30-month stay on approval of a generic drug by the Food and Drug Administration (FDA) while patent litigation involving the reference (brand-name) drug is ongoing.

Generally, entities seeking approval of a new drug must provide the FDA with information on patents claiming the drug or a method of use. Entities seeking approval of a generic drug must certify for each such patent on the reference drug that (1) the patent has expired or will expire before the generic is marketed, or (2) the patent is invalid or inapplicable to the generic drug. If a generic drug applicant certifies that a patent is invalid or inapplicable and a patent infringement suit is timely brought, the FDA is prohibited from approving the generic for 30 months (unless the patent litigation is resolved sooner). Under current law, this 30-month stay applies to patent litigation on any number of patents on a reference drug, provided the patent information was filed with the FDA before the generic application.

Under the bill, when an entity applies to the FDA for approval of a new drug, the entity must select only one patent to be eligible for the 30-month stay. This selection may not be changed or amended. After the bill’s enactment, only patent litigation related to the reference drug’s selected patent may trigger the 30-month stay on approval of a generic.

Sponsors

Sen. Richard Durbin (D) sponsors S. 2620, and 1 member has co-sponsored it from the day it was introduced.

Committees

S. 2620 went before 1 committee: Health, Education, Labor, and Pensions.

Health, Education, Labor, and Pensions
Health, Education, Labor, and Pensions
Referred To · Jul 31, 2025 · 747 Bills

Actions

S. 2620 has taken 2 actions since Jul 31, 2025.

ChamberAction
Jul 31, 2025
Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000)Health, Education, Labor, and Pensions Committee
Jul 31, 2025
Introduced in Senate

Votes

S. 2620 has not gone to a roll call.

Titles

S. 2620 goes by 4 titles, 2 of them short titles.

  • REMEDY Act — Display Title
  • REMEDY Act — Short Title(s) as Introduced
  • Reforming Evergreening and Manipulation that Extends Drug Years Act — Short Title(s) as Introduced
  • A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications. — Official Title as Introduced

Lobbying

7 clients hired 7 firms and 93 registered lobbyists who named S. 2620 in 18 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Budget/Appropriations, Copyright/Patent/Trademark, Pharmacy, Trade (domestic/foreign), Taxation/Internal Revenue Code, Insurance.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)District of Columbia14
GSK (FKA GLAXOSMITHKLINE INC.)District of Columbia14
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICADistrict of Columbia14
AARPDistrict of Columbia12
KAISER FOUNDATION HEALTH PLAN INCCalifornia12
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCDistrict of Columbia11$130K
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATIONno changeDistrict of Columbia11

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 93.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 first_quarter$12.2M1st Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 third_quarter$9M3rd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 fourth_quarter$8.4M4th Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 second_quarter$7.4M2nd Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2026 first_quarter$5.3M1st Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2025 third_quarter$4.2M3rd Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2025 fourth_quarter$4.1M4th Quarter - Report
AARPAARP2026 first_quarter$3.8M1st Quarter - Report
AARPAARP2025 third_quarter$3.8M3rd Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2026 second_quarter$3M2nd Quarter - Report
KAISER FOUNDATION HEALTH PLAN INCKAISER FOUNDATION HEALTH PLAN INC.2026 first_quarter$3M1st Quarter - Report
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATIONPHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2025 third_quarter$2.9M3rd Quarter - Report
GSK (FKA GLAXOSMITHKLINE INC.)GSK (FKA GLAXOSMITHKLINE INC.)2025 third_quarter$1.7M3rd Quarter - Report
GSK (FKA GLAXOSMITHKLINE INC.)GSK (FKA GLAXOSMITHKLINE INC.)2026 first_quarter$1.6M1st Quarter - Report
GSK (FKA GLAXOSMITHKLINE INC.)GSK (FKA GLAXOSMITHKLINE INC.)2026 second_quarter$890K2nd Quarter - Report
GSK (FKA GLAXOSMITHKLINE INC.)GSK (FKA GLAXOSMITHKLINE INC.)2025 fourth_quarter$810K4th Quarter - Report
KAISER FOUNDATION HEALTH PLAN INCKAISER FOUNDATION HEALTH PLAN INC.2026 second_quarter$530K2nd Quarter - Report
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP2025 third_quarter$130K3rd Quarter - Report

Classification

The Congressional Research Service files S. 2620 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; S. 2620’s is Health.

s2620/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Source: congress.gov · legiscan.com